XSpray Pharma AB (XSPRAY) - Total Liabilities

Latest as of March 2026: Skr167.03 Million SEK ≈ $17.98 Million USD

Based on the latest financial reports, XSpray Pharma AB (XSPRAY) has total liabilities worth Skr167.03 Million SEK (≈ $17.98 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

XSpray Pharma AB - Total Liabilities Trend (2015–2025)

This chart illustrates how XSpray Pharma AB's total liabilities have evolved over time, based on quarterly financial data. See how liquid is XSpray Pharma AB's working capital to evaluate short-term liquidity relative to the company's equity base.

XSpray Pharma AB Competitors by Total Liabilities

The table below lists competitors of XSpray Pharma AB ranked by their total liabilities.

Company	Country	Total Liabilities
Champions Oncology Inc NASDAQ:CSBR	USA	$24.07 Million
Deutsch Motors Inc KQ:067990	Korea	₩1.30 Trillion
Adhi Karya Persero Tbk JK:ADHI	Indonesia	Rp24.69 Trillion
Se Gyung Hi Tech Co.Ltd KQ:148150	Korea	₩111.76 Billion
seha corporation KO:027970	Korea	₩273.11 Billion
Houston American Energy Corporation NYSE MKT:HUSA	USA	$12.34 Million
Kalleback Property Invest AB ST:KAPIAB	Sweden	Skr668.05 Million
Jiin Ming Industry Co Ltd TWO:3230	Taiwan	NT$345.61 Million

Liability Composition Analysis (2015–2025)

This chart breaks down XSpray Pharma AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see XSpray Pharma AB (XSPRAY) market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.02	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.29	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.23	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how XSpray Pharma AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for XSpray Pharma AB (2015–2025)

The table below shows the annual total liabilities of XSpray Pharma AB from 2015 to 2025.

Year	Total Liabilities	Change
2025-12-31	Skr164.70 Million ≈ $17.72 Million	-4.94%
2024-12-31	Skr173.25 Million ≈ $18.64 Million	+141.12%
2023-12-31	Skr71.85 Million ≈ $7.73 Million	+144.30%
2022-12-31	Skr29.41 Million ≈ $3.17 Million	-5.59%
2021-12-31	Skr31.15 Million ≈ $3.35 Million	+37.13%
2020-12-31	Skr22.72 Million ≈ $2.44 Million	-15.73%
2019-12-31	Skr26.96 Million ≈ $2.90 Million	+150.32%
2018-12-31	Skr10.77 Million ≈ $1.16 Million	+87.17%
2017-12-31	Skr5.75 Million ≈ $619.17K	+6.78%
2016-12-31	Skr5.39 Million ≈ $579.83K	+100.45%
2015-12-31	Skr2.69 Million ≈ $289.27K	--

About XSpray Pharma AB

ST:XSPRAY Sweden Biotechnology

Market Cap

$79.81 Million

Skr741.60 Million SEK

Market Cap Rank

#20162 Global

#357 in Sweden

Share Price

Skr15.64

Change (1 day)

-0.76%

52-Week Range

Skr14.50 - Skr63.40

All Time High

Skr258.00